Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.35 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 6/20 | 0.33 |
| ▸ | PRKCA | P17252 | 1/20 | 0.32 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL584574 | 1.00 | RXRA (0.39) | RXRARXRBRXRGSLC5A1SLC5A2 | |
| SCHEMBL27911346 | 0.82 | TAAR1 (0.46) | — | |
| SCHEMBL588412 | 0.82 | RXRA (0.36) | RXRARXRBRXRGSLC5A1SLC5A2 | |
| SCHEMBL27839629 | 0.81 | DRD2 (0.40) | RXRARXRBRXRG | |
| SCHEMBL27839630 | 0.81 | DRD2 (0.40) | RXRARXRBRXRG | |
| SCHEMBL11898474 | 0.81 | RXRA (0.42) | RXRARXRBRXRGGRIA2 | |
| SCHEMBL27857416 | 0.79 | CA1 (0.36) | SLC5A1SLC5A2CA1CA2CA12 | |
| SCHEMBL11898633 | 0.79 | NOTUM (0.44) | CA1CA2CA12CA7CA14 | |
| SCHEMBL7898428 | 0.79 | NOTUM (0.44) | CA1CA2CA12CA7CA14 | |
| SCHEMBL11898524 | 0.79 | GRIA2 (0.56) | GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633237-B2 | Indane derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-01-21 | — | — | US | disclosed |
| EP-2417101-B1 | INDANE DERIVATIVES | MERCK SHARP & DOHME (NL) | 2013-10-23 | — | — | EP | disclosed |
| US-20120202781-A1 | INDANE DERIVATIVES | MSD OSS B.V. (NL) | 2012-08-09 | — | — | US | disclosed |
| EP-2417101-A1 | INDANE DERIVATIVES | MSD Oss B.V. (NL) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010115952-A1 | INDANE DERIVATIVES | N.V. ORGANON (NL) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202781-A1 | INDANE DERIVATIVES | CHRNA5, CHRNA2, GRIK5 | RXRA 734/4885RXRB 762/4885RXRG 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.